The integrin ITGAV is a target of TAZ, but not YAP, in hepatocellular carcinoma, and it is associated with poor clinical outcome, indicating unique roles of TAZ in oncogenesis [130]. This evidence concerns the gene YAP1 and hepatocellular carcinoma.